NASDAQ:BRNS Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis $0.74 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Barinthus Biotherapeutics Stock (NASDAQ:BRNS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BRNS alerts:Sign Up Key Stats Today's Range$0.74▼$0.7450-Day Range$0.56▼$0.7852-Week Range$0.51▼$1.83VolumeN/AAverage Volume83,130 shsMarket Capitalization$30.23 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing T-cell immunotherapies for autoimmune diseases. The company’s approach is designed to selectively modulate disease-causing immune responses while preserving normal immune function. Its lead programs include VTP-1000, an investigational therapy being developed for celiac disease, and VTP-300, an immunotherapy candidate for chronic hepatitis B virus infection. Barinthus also maintains a broader pipeline of T-cell therapies based on its proprietary SNAP-T and TRi-STAR platforms, which are intended to generate targeted and durable immune responses. Headquartered in the United Kingdom, Barinthus conducts research and clinical development activities internationally. The company was previously known as Barinthus Therapeutics plc and is led by Chief Executive Officer William Enright. Its ordinary shares trade on the Nasdaq Global Select Market under the symbol BRNS.AI Generated. May Contain Errors. Read More Barinthus Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreBRNS MarketRank™: Barinthus Biotherapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 633rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingBarinthus Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialBarinthus Biotherapeutics has a consensus price target of $4.00, representing about 440.5% upside from its current price of $0.74.Amount of Analyst CoverageBarinthus Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Barinthus Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Barinthus Biotherapeutics are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Barinthus Biotherapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Barinthus Biotherapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBarinthus Biotherapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Barinthus Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently increased by 46.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBarinthus Biotherapeutics does not currently pay a dividend.Dividend GrowthBarinthus Biotherapeutics does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.50% of the stock of Barinthus Biotherapeutics is held by insiders.Percentage Held by Institutions25.20% of the stock of Barinthus Biotherapeutics is held by institutions.Read more about Barinthus Biotherapeutics' insider trading history. Receive BRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BRNS Stock News HeadlinesBarinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsAugust 24, 2026 | globenewswire.comBarinthus Biotherapeutics PLC ADR BRNSJuly 3, 2026 | morningstar.comMA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNSMay 11, 2026 | businesswire.comBarinthus Biotherapeutics: Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApril 30, 2026 | finanznachrichten.deBarinthus in Green on Bringing Out Quarterly NumbersApril 30, 2026 | baystreet.caBarinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApril 30, 2026 | globenewswire.comBarinthus Biotherapeutics plc Sponsored ADRApril 10, 2026 | edition.cnn.comSee More Headlines BRNS Stock Analysis - Frequently Asked Questions How have BRNS shares performed this year? Barinthus Biotherapeutics' stock was trading at $0.7001 at the beginning of 2026. Since then, BRNS stock has increased by 5.7% and is now trading at $0.7401. How were Barinthus Biotherapeutics' earnings last quarter? Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. When did Barinthus Biotherapeutics IPO? Barinthus Biotherapeutics (BRNS) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. How do I buy shares of Barinthus Biotherapeutics? Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Barinthus Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Barinthus Biotherapeutics investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), Cogent Communications (CCOI), Datadog (DDOG), Intuitive Surgical (ISRG), nCino (NCNO) and Construction Partners (ROAD). Company Calendar Last Earnings8/07/2026Today9/28/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BRNS's financial health is in the Red zone, according to TradeSmith. BRNS has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BRNS Previous SymbolNASDAQ:BRNS CIK1828185 Webwww.barinthusbio.com Phone44-1865-818-808FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Price Target for Barinthus Biotherapeutics$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+440.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-59.15% Return on Assets-43.80% Debt Debt-to-Equity RatioN/A Current Ratio5.54 Quick Ratio5.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book0.41Miscellaneous Outstanding Shares40,849,000Free Float37,377,000Market Cap$30.23 million OptionableN/A Beta-0.37 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BRNS) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our Partners"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredIgnore oil - This is the Energy Story of the century…A drilling crew in Utah punched through three miles of granite in 16 days, a job the Department of Energy said...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
